Is GENMAB A/S (GMAB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 32.6% / 30% | 10.3% / 30% | 6.9% / 30% | 3.71% / 5% | ✗ NOT HALAL |
| DJIM | 32.6% / 33% | 10.3% / 33% | 6.9% / 33% | 3.71% / 5% | ✓ HALAL |
| MSCI | 42.2% / 33% | 13.3% / 33% | 8.9% / 33% | 3.71% / 5% | ✗ NOT HALAL |
| S&P | 32.6% / 33% | 10.3% / 33% | 6.9% / 33% | 3.71% / 5% | ✓ HALAL |
| FTSE | 42.2% / 33% | 13.3% / 33% | 8.9% / 50% | 3.71% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 93.6% | |
| Operating Margin | 23.0% | |
| Net Margin | 25.9% | |
| Return on Equity (ROE) | 17.5% | |
| Return on Assets (ROA) | 8.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $1.2B |
| Free Cash Flow | $1.1B |
| Total Debt | $5.4B |
| Debt-to-Equity | 92.8 |
| Current Ratio | 2.0 |
| Total Assets | $12.9B |
Price & Trading
| Last Close | $26.03 |
| 50-Day MA | $29.47 |
| 200-Day MA | $28.05 |
| Avg Volume | 1.7M |
| Beta | 0.8 |
|
52-Week Range
$17.23
| |
About GENMAB A/S (GMAB)
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is GENMAB A/S (GMAB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), GENMAB A/S is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is GENMAB A/S's debt ratio?
GENMAB A/S's debt ratio is 32.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 42.2%.
What are GENMAB A/S's key financial metrics?
GENMAB A/S has a market capitalization of $15.9B, trailing P/E ratio of 16.8, and revenue of $3.7B. The company maintains a gross margin of 93.6% and a net margin of 25.9%. Return on equity stands at 17.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.